The document discusses a workshop on therapeutics as an evolving sector, with speakers from Solvotrin Therapeutics and Enterprise Ireland. It outlines several team brainstorming sessions where ideas were proposed around linking universities, SMEs, and multinational companies in areas like cellular assets, clinical trials funding, and startup support. The overall goal was to explore opportunities to strengthen collaboration between academia and industry in therapeutics.

1. Theme: Therapeutics –
evolving and growing sector
Location: UCC,
Western Gateway Building, Cork
Date: Tuesday15th February 2011
© DOLMEN 2010

2. Sean McNulty, MD
Dolmen / INNOVATOR is a leading
consultancy providing innovation management
and design services to our clients in diverse
markets.
WHO I AM
© DOLMEN 2010

3. SPE AKERs
Mark Ledwidge, PhD
Founder & VP Strategy, Solvotrin
Therapeutics Ltd.
Christian Stafford, PhD
Senior Commercialisation Specialist,
Lifescience & Food Commercialisation
Group ( EI Bio)
Enterprise Ireland
© DOLMEN 2010

4. a Generation 1. Ideas:
Team Ide Idea gathering
Group Ideas
2. Develop Opportunities:
Map Opportunities
Select Opportunities
Share Opportunities
3. Business Feasibility:
Develop the Business
potential
Rate your business
feasibility!
© DOLMEN 2010

5. TEAM 1
IDENTIFY CELLULAR ASSETS
© DOLMEN 2010

6. se ts
aseting
la-rmark
ce llu > •Cellular arrays
tifyity ->
IdenUnivers •Primary Cells •Royalty
•Toxicology •IP legal
•Stream-lined decision time •Cost of patents and cell lines
•Commercialisation focus •Cell banks
•Devils advocate
•Preclinical •Personalised med
•Pre Ind
•Deposit bank of information
•Identification process
Ger Fitz (Micro)
•Value
•Broadband in a box Brand
•Product for sale
•Brand as commodity Benefits:
•Linking into catelogues • University revenue generation
Co-cost of entry:
•Marketing commodities • Centralising through single conduit.
•Cell lines •International access.
© DOLMEN 2010

7. ity
tun
or ng
pp pi TITLE: SILVERCELL
. O ap
2 M
The ideas Describe the solution - Customer
• Existing certified storage GLP concept/system Identify what is the target market?
Who is the customers? End users? Other
• Licensed by the IMB beneficiaries?
• Facilitate the international - Toxicologists
trade of cells and tissues. - Pharma
• Direct link with Pharmacies. - Dry discon.
• Create revenue for
What are the benefits?
Univeristies
-University revenue generation.
• Make research sustainable
Cost efficient centralised
• In future Industry will require
process. International single
safety and ….. On human tissue
brand.
and cells.
• Toxicity testing © DOLMEN 2010

8. TEAM 2
LINKSYN IN 51ST STATE
© DOLMEN 2010

9. n g
rtunit y M ap p i
2. Oppo TITLE: LINKSYN IN 51st STATE
The ideas Describe the solution - Customer
concept/system Identify what is the target market?
• PROFILE TARGET MATCH Who is the customers? End users? Other
beneficiaries?
• NETWORK - HOW TO LEVERAGE LOCAL
-MNCs + SMEs.
• ‘Irish Mafia’ Techlink. Team of FOOTPRINT BY DEVELOPING
experts LOCAL NETWORKS.
• BARE PIPELINE
• R&D
What are the benefits?
• NICHE EXPERTISE - FUNDING COLLABORATION.
• Id: decision makers, HQ MARKET ACCESS. JOBS. TAX.
contacts
© DOLMEN 2010

10. ig
a rma + b
se of big Ph print in
anced u
• Unused IP
t
E nh d tech foo
+ big me efit of SMEs.
• License money
food en
nd for b
• What do SMEs need?
Irela • Money market resources
• How not to get swallowed?
• Contacts to HQ
•Path to market
• How to leverage local footprint.
• Linksyn in the 51st State
• Customer- an individual or a group within a …
•Customer decision makers.
• Value proposition
• Profile multinationals • Research Vs Development
• Match company profile to your offering • Niche expertise
• Incentives • Networks: Bio, Pharma…
•What is in it for local MGR?
• services supplied?
• Irish Mafia
•Broaden pipeline
© DOLMEN 2010

11. TEAM 3
SPIN DOCTORS
© DOLMEN 2010

12. nity M apping
2. Opportu TITLE: SPIN DOCTORS
The ideas Describe the solution - Customer
concept/system Identify what is the target market?
• €5million fund Who is the customers? End users? Other
beneficiaries?
• 20 in 5 Experts in therapeutics will lead
• PI Institution
• market driven evaluation start-ups to success by following
• VC
• Early partner scouting the money from seed to
• Big Pharma Foundations
•Follow the money $millions to exit.
• Business Partners What are the benefits?
•Mentors -Industry experts. Seed funding.
• R&D and production in Right location. Money.
Ireland
• HQ in USA
• Experts
© DOLMEN 2010

13. R
O DEL FO P
EW M TART-U
1. A N UTIC S 2. P
ICK
TH ERAPE AND
‘LAN
PAR D’ TH
TNE E RI
R GHT
• too much focus on start-up? • For Pharma
•Startup US license? • Their needs, market size
• When is the right time? • Data compatible with product roadmap
• What is a good idea? • sales force-IP/patient
• Market size >€1b •Niche
• People-lack of comm skills- sales/mk • Reg status
• No VC infastructure •For startup
• €5m fund 2015 •Source of funding
• Technology evaluation • Routes to market
• Follow the money • Business Plan
• Market driver- R&D!!! • Sale or partnership, (exit), timing
•Scouting Partners early • Value of business/technology
•Reg status
© DOLMEN 2010

14. TEAM 4
NCTFC
© DOLMEN 2010

15. nity M apping
2. Opportu TITLE: NCTFC National Clinical Trials Funding Corp
The ideas Describe the solution - Customer
concept/system Identify what is the target market?
Who is the customers? End users? Other
beneficiaries?
A new funding structure for
• Pis
Clinical trials in Ireland.
•Pharma
•Device
What are the benefits?
-Deliver Phase II trials in Ireland.
- Funding streams
-Health system
-Grow indigenous companies
© DOLMEN 2010

16. o
ment (t
Make develop cient
ore effi
•I.T system
phase II) m •Data management
• Specialist areas
•Pharma
•Sponsor (Directives) •Device
•National Structure
•€250million
•HSE
•2% budget
•Regulatory Ethics
•CRO
•C.R.C’s
•Research nurses
•Revenue Streams
•Funding
•€5-10million
© DOLMEN 2010

17. resentations
P
TEAM
Presentation of
value propositions
for selected
opportunities.
© DOLMEN 2010

18. t happe ns next
Wha
• Complete and return the participant follow up
sheet to your EI Regional Development Executive
• Join the IDEAGEN LinkedIn group
http://www.linkedin.com/groups?gid=2649046&trk=hb_side_g
Keep up to date on latest from IDEAGEN by
• Following on Twitter
http://twitter.com/ideagen
•Becoming a fan on Facebook
http://www.facebook.com/pages/Ideagen/134045788401
© DOLMEN 2010

19. T he End
Thank you
Sean McNulty
smcnulty@dolmen.ie
© DOLMEN 2010